Recently, some groups have shown that the inhibitor of Bruton's tyrosine kinase (BTK) ibrutinib blocks AML cell proliferation, adhesion to bone marrow stromal cells as well as migration [21–23]. Here, BTK is linked to acute myeloid leukemia.